• Home
  • Search Results

Search Results

Young Adult (18-34)
Cancer
416 studies match your search
Not currently enrolling

Dose-escalation and expansion study of BAY 3375968 (anti-CCR8 antibody) as monotherapy and in combination with pembrolizumab in selected advanced solid tumors

This study will evaluate BAY 3375968 as a new immunotherapeutic agent in advanced solid tumor settings of high medical need.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Bladder, Breast, Colorectal, and 5 more)
Open

PRevention Of Frailty with Fisetin (PROFFi) in Breast Cancer Survivors

Are you a breast cancer survivor? if soy you may be eligible to participate in this research study that is looking at the effectiveness of fisetin and/or exercise on physical function assessed using a 6 minute walking distance in chemotherapy-treated postmenopausal breast cancer survivors

Age & Gender
  • 18 years ~ 70 years
  • Female, Gender Inclusive
Study Interest
  • Cancer (Breast)
Open

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Do you have With Locally Advanced or Metastatic Solid Tumors of the Head or Neck? If so, you may be able to participate in a research study to to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®).

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Head and Neck)
Not currently enrolling

Metastatic Non-small Cell Lung Cancer Treatment

In this study, we want to see how patients with metastatic non-small cell lung cancer do with two treatments: ivonescimab and chemotherapy. We are comparing these treatments to find out which one helps patients more.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Lung)
Open

EFFICACY AND SAFETY OF DIVARASIB VERSUS SOTORASIB OR ADAGRASIB IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

Do you have non small cell lung cancer? Are you currently not on any other treatments for your cancer? If you answered yes, you may be able to take part in a lung cancer medication study.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Lung)
Open

Phase 1/2 Study of BDTX-1535 in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR

Do you have a cancer that is advanced or metastatic? Has your cancer progressed on other standard of care therapies? If you answered yes, then this research study may be for you. Study drug will be provided

Age & Gender
  • 18 years ~ 99 years
  • Male, Female
Study Interest
  • Cancer (Lung)
Not currently enrolling

Myeloma Diagnosis Study

We know multiple myeloma can take a long time to diagnose. In this study, we want to better understand how your myeloma was diagnosed so we can identify ways to improve the process.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Multiple Myeloma)
  • Minority Health
Visit Location
100% Remote (online, phone, text)
Not currently enrolling

Physical Activity Treatment Study

In this study, we want to help Black and African American people who have had colon cancer, rectal cancer, or colorectal cancer. We want to see if an exercise program can help with cancer side effects and overall quality of life.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Colorectal)
  • Wellness and Lifestyle
  • Movement
Visit Location
100% Remote (online, phone, text)
Open

Relapsed Peripheral T-cell Lymphoma Treatment Study

Do you have relapsed peripheral T-cell lymphoma (PTCL)? Has your cancer not gotten better with other treatments, or were those treatments stopped because of bad side effects? If so, you might be able to join a study to see if a new drug called Soquelitinib (also known as CPI-818) can treat PTCL better.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Blood Conditions
  • Cancer (Lymphoma)
Open

IDH-Wildtype Glioblastoma Treatment Study

Are you an adult who has just found out you have IDH-Wildtype Glioblastoma? If so, you could join a study to see if a new experimental pill called ropidoxuridine can help make treatment for this type of brain cancer better when used with radiation.

Age & Gender
  • 18 years ~ 99 years
  • Male, Female, Gender Inclusive
Study Interest
  • Cancer (Brain and Other Nervous System)
Research for Me logo

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Questions?

  • This email address is being protected from spambots. You need JavaScript enabled to view it.
logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research